Health Johnson & Johnson’s Imaavy Faces Setback in Arthritis Trials Johnson & Johnson’s new immunology drug, Imaavy, has encountered a significant setback as it failed to meet its primary endpoints in a Phase 2a... Editorial3 hours ago